Association of the von Willebrand Factor–ADAMTS13 Ratio With Incident Cardiovascular Events in Patients With Peripheral Arterial Disease

Background: Platelet adhesion is mediated by von Willebrand factor (vWF), and disintegrin-like and metalloprotease domain with thrombospondin type-1 motif, number 13 (ADAMTS13) is a protease that cleaves vWF. A change in the balance between vWF and ADAMTS13 in favor of thrombosis might occur shortly before ischemic cardiovascular (CV) events. Objective: To determine whether vWF, ADAMTS13, and the ratio of vWF and ADAMTS13 change during the months preceding an acute CV event. Design: Prospective longitudinal observational study. Setting: Outpatient. Patients: A total of 595 participants with peripheral artery disease (PAD). Measurements: Blood samples were obtained every 2 months for up to 3 years and hemostatic factors examined at intervals preceding events. Results: Sixty-one participants (cases) experienced events and were matched to 122 PAD controls. During the 2-month interval prior to an event, cases (n = 48) had higher levels of the vWF and ADAMTS13 than controls (n = 95; P = .05), but significance was lost after adjusting for the baseline differences in myocardial infarction, unstable angina, and stroke. During the 10 months prior to an event, median values for vWF and the ratio of vWF and ADAMTS13 were higher in cases than in controls, but the differences were not statistically significant. However, in a subset of 20 patients with complete bimonthly data, there was a trend toward an increase in the ratio in the 10 months prior to a CV event (P = .04). Conclusion: In patients with PAD experiencing an ischemic CV event, a significant increase in the ratio of vWF to ADAMTS13 prior to the event could not be confirmed, although there was a weak trend in this direction.

[1]  Sanjiv J. Shah,et al.  Changes in D-dimer and inflammatory biomarkers before ischemic events in patients with peripheral artery disease: The BRAVO Study , 2016, Vascular medicine.

[2]  A. Hofman,et al.  Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. , 2015, Blood.

[3]  S. Cessie,et al.  Plasma ADAMTS‐13 levels and the risk of myocardial infarction: an individual patient data meta‐analysis , 2015, Journal of thrombosis and haemostasis : JTH.

[4]  A. Bryer,et al.  High Levels of von Willebrand Factor and Low Levels of its Cleaving Protease, ADAMTS13, are Associated with Stroke in Young HIV-Infected Patients , 2015, International journal of stroke : official journal of the International Stroke Society.

[5]  P. Sidhu,et al.  Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke , 2015, Journal of the Neurological Sciences.

[6]  J. Goldberger,et al.  The association between sleep characteristics and prothrombotic markers in a population-based sample: Chicago Area Sleep Study. , 2014, Sleep medicine.

[7]  Sanjiv J. Shah,et al.  Vulnerable blood in high risk vascular patients: study design and methods. , 2014, Contemporary clinical trials.

[8]  P. Kamphuisen,et al.  Reduced prevalence of arterial thrombosis in von Willebrand disease , 2013, Journal of thrombosis and haemostasis : JTH.

[9]  S. D. De Meyer,et al.  Unwinding the von Willebrand factor strings puzzle. , 2013, Blood.

[10]  B. Nieswandt,et al.  Size does matter: VWF in MI. , 2012, Blood.

[11]  M. M. Jadaon,et al.  Smoking, von Willebrand factor and ADAMTS-13 in healthy males , 2012, Scandinavian journal of clinical and laboratory investigation.

[12]  P. Whincup,et al.  Fibrin D-Dimer, Tissue-Type Plasminogen Activator, von Willebrand Factor, and Risk of Incident Stroke in Older Men , 2012, Stroke.

[13]  A. Algra,et al.  High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. , 2012, Blood.

[14]  Dong Chen,et al.  Left Atrial Blood Stasis and Von Willebrand Factor–ADAMTS13 Homeostasis in Atrial Fibrillation , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[15]  J. Deckers,et al.  Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. , 2011, Blood.

[16]  K. Huber,et al.  Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation , 2010, Thrombosis and Haemostasis.

[17]  J. Pankow,et al.  Hemostasis, Inflammation, and Fatal and Nonfatal Coronary Heart Disease: Long-Term Follow-Up of the Atherosclerosis Risk in Communities (ARIC) Cohort , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[18]  K. Kaikita,et al.  Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation. , 2009, Thrombosis research.

[19]  J. Sadler Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. , 2008, Blood.

[20]  M. Woodward,et al.  Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack , 2008, Journal of thrombosis and haemostasis : JTH.

[21]  G. Lip,et al.  Changes in von Willebrand factor and soluble ICAM, but not soluble VCAM, soluble E selectin or soluble thrombomodulin, reflect the natural history of the progression of atherosclerosis. , 2002, Atherosclerosis.

[22]  J. Danesh,et al.  von Willebrand factor and coronary heart disease: prospective study and meta-analysis. , 2002, European heart journal.

[23]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[24]  J. Vermylen,et al.  atherosclerosis-prone sites in response to hypercholesterolemia Endothelial von Willebrand factor recruits platelets to , 2013 .

[25]  R. Hynes,et al.  Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. , 2000, Blood.

[26]  A. Folsom,et al.  Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1999, Circulation.

[27]  A. Folsom,et al.  Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. , 1996, Journal of clinical epidemiology.

[28]  P. Keith,et al.  Older Men , 1981 .